News
-
27th November 2020 - Press notes
The MAPBM (Maturity Assessment Model for Patient Blood Management) project makes it easier for hospitals to adjust transfusions and is the key to properly managing hospital blood reserves at a time when donations are falling sharply as a result of measures to prevent the spread of COVID-19. In five years, this project, promoted by the Hospital del Mar Medical Research Institute, has already reached around sixty hospitals in Spain. This success demonstrates the feasibility of implementing the model and making it a tool for improving both patient safety and outcomes, according to a study just published in the journal Blood Transfusion. Hospital del Mar stands out in this field and has been awarded at the annual meeting of the hospitals participating in the project as the center without cardiac surgery with the best results.
more information
-
3rd November 2020 - Press notes
A joint study by physicians at Hospital del Mar, researchers from the Hospital del Mar Medical Research Institute, Pompeu Fabra University and the Pere Virgili Health Care Park suggests that certain drugs used to treat this condition are safe for COVID-19 patients and could even have a protective effect. The results support the recommendations of the scientific guidelines relating to the desirability of maintaining treatments for osteoporosis in patients with COVID-19. This is the first study of its kind in the world. It has just been published in the journal Aging.
more information
-
8th October, 2020 - Press notes
A study by researchers from Hospital del Mar and the Hospital del Mar Medical Research Institute reveals the protective effect that 30 minutes of moderate physical activity per day can have, as recommended by the World Health Organisation. Multiplying this figure by four maximises the benefit, but, beyond this, there is no additional benefit. The study, published by the Revista Española de Cardiología (Spanish Journal of Cardiology), has been monitoring over 11,000 people for more than 7 years.
more information
-
October 2nd, 2020 - Press notes
Benign breast diseases (BBD), which are non-cancerous disorders of the breast, such as lumps, are known to increase the chances of subsequent breast cancer. Now a team of Hospital del Mar researchers have found that the way BBD is detected as part of a national screening programme is an indication of which are more likely to become cancerous.
more information
-
15/09/2020 - Press notes
This discovery may provide new treatment strategies and therapeutic targets for important diseases such as cancer or Alzheimer's
The research group of GPCR Drug Discovery at the Hospital del Mar Medical Research Institute (IMIM), in collaboration with the Indian Institute of Technology in Kanpur, has deciphered how nature adjusts the response of the human cell to abundant extracellular stimuli (e.g., smell, taste, light, hormones, etc.).
more information
-
September 3rd 2020 - Press notes
Arnau Busquets-García, an IMIM researcher, receives an ERC Starting Grant for scientific excellence.
more information
-
July 9th 2020 - Press notes
Dr. Arnau Busquets, currently a Ramon y Cajal researcher in the IMIM's Integrated Pharmacology and Systems Neuroscience Research Group is one of the first authors of this work.
more information
-
June 30th 2020 - Press notes
The successful projects are "Obtaining antioxidant active substances from the carob pod and validating their therapeutic potential", which involves the company Euronutra, the IBIMA (Malaga Biomedical Research Institute), the IMIM (Hospital del Mar Medical Research Institute), and the CRG (Centre for Genomic Regulation); and the project "Development of a new therapy for Fragile X syndrome", in which the company Connecta Therapeutics, the IMIM, and the CRG are participating.
more information
-
May 28th 2020 - Press notes
The MINDUP project began in January 2020 to support SMEs in the mental health care of their workers. Now adapting to the COVID-19 pandemic and highlighting its usefulness in current circumstances.
more information
-
May 25th 2020 - Press notes
The company Chemotargets -based in the Barcelona Science Park and a leader in in the global market as a provider of intelligence and drug design prediction platform- has signed a strategic agreement with the Hospital del Mar Medical Research Institute (IMIM) to discovery and development of new oncological therapies that respond to important unmet medical needs.
more information